Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel S Goodman

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
JMIR Dermatology|September 7, 2023
Public Health Risks, Dermatological Manifestations, and Environmental Justice Associated With Vinyl Chloride Exposure: Narrative ReviewRachel S Goodman, Lavanya Mittal, Eva Rawlings Parker
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Corticosteroids and Cancer ImmunotherapyRachel S Goodman, Douglas B Johnson, Justin M Balko
The Oncologist|June 20, 2023
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case SeriesRachel S Goodman, Seungyeon Jung, Jessica Quintos, et al.
Immunological Reviews|July 20, 2023
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunitiesRachel S Goodman, Seungyeon Jung, Justin M Balko, et al.
Med (New York, N.Y.)|March 11, 2023
On the cusp: Considering the impact of artificial intelligence language models in healthcareRachel S Goodman, J Randall Patrinely, Travis Osterman, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2023
Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanomaRachel S Goodman, Joy Justice, Laura J Gardner, et al.
JAAD International|July 6, 2023
Cost assessment in melanoma clinical trials: A cross-sectional studyRachel S Goodman, Desmond C Garner, Stefan Koester, et al.
Cancers|July 13, 2024
Primary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort StudyRachel S Goodman, Seungyeon Jung, Kylie Fletcher, et al.
JAMA Network Open|August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected MelanomaRachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
JAMA Dermatology|March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint InhibitorsKylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
JMIR Dermatology|September 7, 2023
Public Health Risks, Dermatological Manifestations, and Environmental Justice Associated With Vinyl Chloride Exposure: Narrative ReviewRachel S Goodman, Lavanya Mittal, Eva Rawlings Parker
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Corticosteroids and Cancer ImmunotherapyRachel S Goodman, Douglas B Johnson, Justin M Balko
The Oncologist|June 20, 2023
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case SeriesRachel S Goodman, Seungyeon Jung, Jessica Quintos, et al.
Immunological Reviews|July 20, 2023
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunitiesRachel S Goodman, Seungyeon Jung, Justin M Balko, et al.
Med (New York, N.Y.)|March 11, 2023
On the cusp: Considering the impact of artificial intelligence language models in healthcareRachel S Goodman, J Randall Patrinely, Travis Osterman, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2023
Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanomaRachel S Goodman, Joy Justice, Laura J Gardner, et al.
JAAD International|July 6, 2023
Cost assessment in melanoma clinical trials: A cross-sectional studyRachel S Goodman, Desmond C Garner, Stefan Koester, et al.
Cancers|July 13, 2024
Primary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort StudyRachel S Goodman, Seungyeon Jung, Kylie Fletcher, et al.
JAMA Network Open|August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected MelanomaRachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
JAMA Dermatology|March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint InhibitorsKylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
Pageof 2